Specialists respond to Estol: “Sinopharm is very effective”

After the neurologist’s statements Conrado Estol, who spoke about the effectiveness of vaccines made in China and felt that “You don’t need to buy more from Sinopharm”, two specialists reaffirmed the importance of these doses to fight against the pandemic, and assured that “It’s very effective” in the prevention of severe forms of Covid-19.

“I wouldn’t buy more from Sinopharm. There is strong evidence on the planet led by data from Seychelles, Mongolia, Chile, Uruguay, the countries that have vaccinated the most, which showed that the Chinese vaccines from Sinovac and Sinopharm were already much less effective before the onset of Delta, ”he said. Conrado Estol in dialogue with Marcelo Longobardi for Radio bolster.

Eduardo López, infectologist at the Ricardo Gutiérrez children’s hospital and member of the expert committee advising the government on the pandemic, explained in dialogue with PROFILE that it is a vaccine that has more than 69% effective for all forms of coronavirus and 91% to prevent severe cases.

Sinopharm: the government is preparing 10 flights to China to bring 8 million doses

“Sinopharms are not throwaway vaccines. If they are vaccinated intensively, even if they are less effective than others, they are still very useful. The best example is Chile, which uses Corona Vac, which is similar to Sinopharm: by vaccinating intensely with two doses, the cases have decreased, ”López told this outlet.

“The data that the Sinopharm laboratory gave is that it is more than 69% effective for all forms of Covid-19, and 91% for severe forms,” ​​he said.

López also pointed out that the Sinopharm vaccine, of which Argentina already has six million doses, “It has been endorsed by the Strategic Advisory Group of Experts (SAGE) of the World Health Organization.”

Regarding the efficacy against the new variants of covid-19, although there are still no studies on this subject, he clarified: “It is possible that with the new variant Delta, which is not yet in Argentina, this vaccine can reduce the effectiveness, but it is still very useful in two doses, especially in the over 60 years, because 78% of the deaths are there ”, explained the specialist.

The city of Buenos Aires will test the combination of Sputnik V, AstraZeneca and Sinopharm

“Chile continues to vaccinate, it is true that they have had epidemics, but that they were managed with the same vaccine. Otherwise, there is always the possibility of giving a third dose, ”he added of the health situation in this country, which mainly used doses made in China in its vaccination campaign.

In the same line it was shown Jorge geffner, immunologist and researcher at CONICET. “The vaccine is very effective in preventing serious infection, by 70%.”

“It’s a less efficient step in terms of transmitting infection from person to person, but about 70% effective. I buy it right away ”, assured Geffner in dialogue with the program. Fantino in the afternoon, which is broadcast on the channel America, regarding Estol’s statements.

Conrado Estol, stranded in the United States: “It looks like a punishment for those who can travel to be vaccinated”

24 million Sinopharm vaccines will arrive in the next three months

Argentina has already received six million vaccines from Sinopharm in recent months, and the government has announced a contract for 24 million more doses that will arrive in shipments of eight million in July, August and September.

In the coming days, 10 flights will leave for China: the first would leave tomorrow, Friday July 2, to Beijing. In the meantime, the nine remaining flights would take off on Wednesday July 7, at the rate of one per day.

In each of them, at least 800,000 vaccines will be shipped, a figure that could change depending on the vaccines the laboratory manages to pack, in addition to the capacity of the aircraft.

Argentina has already received 26 million vaccines against the coronavirus: 10,124,830 from Sputnik V, 6 million from Sinopharm; 580,000 from AstraZeneca-Covishield; 1,944,000 AstraZeneca by COVAX and 7,057,900 by AstraZeneca and Oxford.

AG CP